Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026. …
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Pharmac announces plan to revise it recently expanded patient advisory function
August 4, 2026 - - Latest News -
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - - Latest News -
This complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News